RxDoctor Payments Data

Kaitlin Park

Family · Michigan City, INNPI 1083324867

Payments from drug & device makers

$2,065in general payments, 2019–2025

Across 120 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$475
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$388
  • Merck$230
  • Chiesi USA, Inc.$154
  • Abbott$120
  • Actelion Pharmaceuticals US, Inc.$108
  • plus $589 from 14 others

What the payments were for

  • Food & beverage$1,97696%
  • Education$894%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,065 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$32,695
Medicare patients
225
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$48,323
EntrestoSacubitril/Valsartan30$43,365
BrilintaTicagrelor19$20,443
XareltoRivaroxaban18$17,825
Diltiazem 24hr Er (Cd)Diltiazem Hcl63$1,453
Metoprolol Succinate127$1,390
Potassium Chloride18$1,159
Flecainide Acetate17$792
Atorvastatin Calcium113$748
Amiodarone Hcl26$612
Ezetimibe26$500
Isosorbide Mononitrate ErIsosorbide Mononitrate50$496
Rosuvastatin Calcium34$379
Hydralazine Hcl12$367
Losartan Potassium48$364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$48,32342 claims
NovartisEntresto$475$43,36530 claims
Johnson & JohnsonXarelto$105$17,82518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Michigan City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →